Post
-
Plenary I highlights interplay between COVID-19 and autoimmune dysfunction
Plenary Session I focused on growing links between SARS-CoV-2 infection and autoimmune events that are more often seen in rheumatologic diseases.
-
Plenary II: DOACs could be the better choice than warfarin for OA patients
A retrospective analysis of knee and hip replacements in patients with atrial fibrillation on anticoagulation therapy was one of the presentations during the Plenary II session during ACR Convergence 2020.
-
Mavrilimumab reduces flare and increases sustained remission in giant cell arteritis, late-breaking abstract reports
The ACR Convergence 2020 Late-Breaking Abstracts session featured six presentations on cutting-edge science.
-
Plenary III: Data shows belimumab improves SLE control, renal outcomes, steroid use
Results from the BLISS-LN trial was one of the highlights from the Plenary III session.
-
Panelists review draft updated ACR guideline for RA management
A new ACR guideline for the management of rheumatoid arthritis (RA) has been drafted and is expected to be approved later this year and published by early spring 2021.
-
Session explores COVID-19 impact on rheumatic disease populations
Members of the Global Rheumatology Alliance (GRA) COVID-19 Steering Committee presented data from the COVID-19 GRA Registry on the impact of the pandemic on the rheumatology community.
-
New ACR leadership confirmed at 2020 Business Meeting
David Karp, MD, PhD, became the 84th ACR President. Additionally, Kenneth G. Saag, MD, MSc, became ACR President-Elect, and Deborah Dyett Desir, MD, was confirmed by the membership as the new ACR Secretary.